WORLD THROMBOSIS DAY SPECIAL EVENT: The Use of D-dimer as a Novel Biomarker in Venous Thromboembolic Disease for Hospitalized Medically Ill Patients

 

Of the 15 million patients admitted to US based hospitals with medical, non-surgical illnesses, 8 million possess inherent risk of blood clots in the venous system, a complication known as venous thromboembolism (VTE). Laboratory-based diagnostic assays, including automated D-dimer tests, can greatly help with clinician management of VTE, especially prevention of blood clots in the lungs, known as pulmonary embolism (PE). Our webinar will provide an overview of previously published trials featuring the role of D-dimer to identify patients at high risk of VTE in the medically ill population, published clinical algorithms to stratify patient risk, as well as breaking literature around management of VTE in medically ill COVID-19 patients.

 

Learning Objectives